The Health, Science & Technology (HST) Group aims to further improve the investment climate for the pharmaceutical industry in Belgium. To this end, the group regularly consults the ministers in charge on topics such as business environment and investments, reimbursement policies and prices, the potential of the sector in the recovery policy, intellectual property and international trade agreements. In 2013 the group prepared various policy recommendations for the federal government.
The HST Group also pays special attention to the training of young people, to development collaboration, to an even more intense collaboration between industry and the academic world, and to rapid and optimal access to innovative medicines.
The HST Group was created in 2006 by Janssen Pharmaceutica NV, UCB, GlaxoSmithKline and Pfizer, all of which invest heavily in research & development in Belgium, and therefore play a major role in the Belgian economy and the employment situation.
Investments in Research & Development are seen as an incentive for (high quality) employment, export and economic growth. Belgium is also an important market for clinical studies in Europe. The report concludes that, with a view to the future, it is important to maintain, and even improve, the competitive advantage of the Belgian biopharmaceutical sector.
It is important to maintain, and even improve, the competitive advantage of the Belgian biopharmaceutical sector.